scispace - formally typeset
M

Matthew Hassink

Researcher at University of Delaware

Publications -  13
Citations -  497

Matthew Hassink is an academic researcher from University of Delaware. The author has contributed to research in topics: Bioconjugation & Tetrazine. The author has an hindex of 6, co-authored 10 publications receiving 450 citations. Previous affiliations of Matthew Hassink include National Institutes of Health.

Papers
More filters
Journal ArticleDOI

Tetrazine-trans-cyclooctene ligation for the rapid construction of 18F labeled probes

TL;DR: A radiolabeling method for bioconjugation based on the Diels-Alder reaction between 3,6-diaryl-s-tetrazines and an (18)F-labeled trans-cyclooctene is described, making it an effective conjugation method within seconds at low micromolar concentrations.
Journal ArticleDOI

Development and Evaluation of 18F-TTCO-Cys40-Exendin-4: A PET Probe for Imaging Transplanted Islets

TL;DR: 18F-TTCO-Cys40-exendin-4 demonstrated its great potential for transplanted islet imaging: the liver uptake value derived from small-animal PET images correlated well with the transplanted β-cell mass determined by immunostaining and the localizations of radioactive signal indeed corresponded to the distribution of islet grafts in the liver of is let-transplanted mice.
Journal ArticleDOI

Tetrazine-trans-cyclooctene ligation for the rapid construction of integrin αvβ₃ targeted PET tracer based on a cyclic RGD peptide.

TL;DR: The development of an extremely fast and efficient method for generating (18)F labeled probes based on the tetrazine-trans-cyclooctene ligation and the receptor specificity was confirmed by blocking experiments.
Journal ArticleDOI

Copper-Catalyzed Synthesis of 2,4-Disubstituted Allenoates from α-Diazoesters

TL;DR: A Cu-catalyzed method for coupling α-substituted-α-diazoesters with terminal alkynes to give substituted allenoates is described and a plausible mechanism is proposed, based in part on evidence against a mechanism that involves a Cu(I)-acetylide as a low-valent intermediate.
Journal ArticleDOI

Preclinical evaluation of a mercaptobenzamide and its prodrug for NCp7-targeted inhibition of human immunodeficiency virus.

TL;DR: Cell to cell transmission of HIV in multiple passages was significantly reduced in CEM-SS and human PBMCs by reducing progeny virus infectivity at compound concentrations greater than 2 μM, which is consistent with the proposed mechanism of action of the virus inactivating compounds.